老年人降压药物相关伤害风险特征:PRIME研究亚组分析
该研究基于英国PRIME前瞻性队列,纳入≥65岁出院后随访8周的住院老年患者,分析服用降压药物者发生药物相关伤害(MRH)的临床与社会人口学特征。服用四种降压药者发生MRH的风险约为服用一种者的五倍(OR 4.96;95%CI 1.63-15.13;P=0.01)。
要点
- 服用四种降压药的老年人发生MRH的风险约为单药者的五倍(OR 4.96;95%CI 1.63-15.13;P=0.01)。
- 降压药物相关MRH事件中80%(n=123)被归类为严重事件,需调整剂量或停药。
- 近半数(49%,n=75)降压药物相关MRH事件潜在可预防。
核心结论
- 老年人降压药物多重用药与可预防的MRH相关,心血管风险降低决策需审慎考虑降压药物带来的MRH。
研究设计与样本
- PRIME为在英国南部开展的前瞻性研究,旨在开发住院老年患者MRH风险分层模型。
- 研究对象为≥65岁成人,从五家教学医院出院时招募并随访8周。
- 通过电话访谈、初级保健记录审查及再入院记录识别MRH。
- 本分析纳入服用降压药物(依据NICE高血压指南定义)的PRIME研究参与者。
主要发现
- 服用四种降压药者发生MRH的可能性为服用一种者的五倍(OR 4.96;95%CI 1.63-15.13;P=0.01)。
- 多数MRH事件被归类为「严重」(80%,n=123),需调整剂量或停止治疗。
- 近半数MRH潜在可预防(49%,n=75)。
关键数值与推荐
- 降压药物依据英国国家卫生与临床优化研究所(NICE)高血压指南定义。
- MRH严重事件定义为需调整剂量或停止治疗的事件。
临床怎么用
- 对服用多种降压药物的老年患者,应关注降压药物相关MRH风险,尤其是四种及以上降压药联用时。
- 在老年人心血管风险降低决策中,需权衡降压药物带来的可预防MRH。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Cardiovascular disease (CVD) is common amongst frail older people. The evidence base for CVD commonly excludes older adults with multimorbidity or chronic conditions. Most cardiovascular drugs have the potential to lower blood pressure (BP) and therefore cause medication-related harm (MRH). We aimed to identify key clinical and sociodemographic characteristics associated with MRH in older people taking BP-lowering drugs for whatever indication they were prescribed. METHODS: The PRIME (prospective study to develop a model to stratify the risk of MRH in hospitalised elderly patients in the UK) study investigating the incidence and cost of MRH in older people across Southern England. Adults ≥65 years were recruited from five teaching hospitals at hospital discharge and followed up for 8 weeks. Telephone interviews with study participants, review of primary care records and hospital readmissions were undertaken to identify MRH. PRIME study participants taking BP-lowering drugs (as defined by National Institute for Health and Care Excellence hypertension guidelines) were included in this analysis. RESULTS: One hundred and four (12%) study patients experienced a total of 153 MRH events associated with BP-lowering drugs. Patients on four BP-lowering drugs were five times more likely to experience MRH compared to those taking one medication (OR 4.96; 95%CI 1.63-15.13; P = 0.01). Most MRH events were classified 'serious' (80%, n = 123), requiring dose change or treatment cessation. Almost half of MRH were potentially preventable (49%, n = 75). CONCLUSION: Polypharmacy from BP-lowering drugs in older people is associated with preventable harm. Decisions around cardiovascular risk reduction should be carefully considered in view of MRH arising from BP-lowering drugs.
引用
- Hussain A, Ali K, Parekh N, et al. Characterising older adults' risk of harm from blood-pressure lowering medications: a sub-analysis from the PRIME study. Age Ageing. 2022. PMID: 35352796. doi:10.1093/ageing/afac045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。